Background: Single therapy with methylphenidate or American ginseng contributes to the reduction in cancer-related fatigue (CRF) with different pharmacologic mechanisms and is relatively safe. However, the safety and efficacy of treating CRF with methylphenidate and AG combination therapy is unknown. Aim: The primary objective was to assess the clinical safety and the change in fatigue with numerical rating scale (NRS) on the Edmonton Symptom Assessment Scale (ESAS) after intervention with methylphenidate and AG combination therapy. Methods: We reviewed the electronic medical records of 857 patients seen in our Palliative Medicine outpatient clinic between February 1, 2015, and December 31, 2015. Fatigue was assessed by NRS on ESAS. Toxicity was reviewed on clinician's documents. Results: We identified 28 patients who were prescribed a combination of methylphenidate (10-40 mg/d) and AG (2000 mg/d). Ten patients did not comply with the combination therapy. Three patients had stage 2 adverse effects. Fifteen patients completed prescribed combination therapy per instructions. The mean time interval between pre-and postintervention follow-up was 30.5 days (standard deviation [SD]: 7.78). There was a significant reduction in the fatigue score (mean score 6.93-4.13) from the pre-to postscore records (mean: À2.8; SD: 1.61; P < .0002* [*refers to statistically significant]). Sixty percent of patients reported significant reduction in fatigue (cutoff value: !3; reduction in fatigue score from baseline: 80% !2, 60% !3, and 46.7% !4). Conclusion: In our retrospective medical record review, the combination treatment of methylphenidate and AG had no discernible associated toxicities and showed potential clinical benefit in CRF.
Introduction
National Comprehensive Cancer Network (NCCN) defines cancer-related fatigue (CRF) as " . . . distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to activity and that interferes with usual functioning" 1 (p. 1020). Fatigue is one of the most common symptoms reported by patients undergoing treatment for cancer, as well as those receiving palliative care, with a measured prevalence of 29% to 80%. 2, 3 It currently remains unclear whether CRF is related to primary cancer type, disease stage, tumor size, extent and length of cancer treatment, time since treatment, or individual predispositions. [4] [5] [6] [7] Cancer-related fatigue adversely affects the patient's daily physical activity and quality of life [8] [9] [10] and is often overlooked by health-care professionals. 11, 12 It has been suggested that fatigue assessment be incorporated as a vital sign in individual assessments. 13 There is limited evidence on the pathophysiology of CRF, although there are several proposed theories. These theories include an association with pro-inflammatory cytokines, hypothalamic-pituitary-adrenal axis dysregulation, circadian rhythm desynchronization, sarcopenia, and genetic dysregulation 13 ( Figure 1 ). Fatigue is a subjective experience, and there are no objective indicators to define it. Most CRF screening or diagnostic tools are based on patient self-report. Severity is the most frequently used domain which guides treatment and is measured simply on a patient's self-reported numerical rating scale (NRS). Several multidimensional screening instruments have been developed and validated. 13 The Edmonton Symptom Assessment Scale (ESAS), which includes an NRS of fatigue, is used for palliative symptom screening at each visit in our Palliative Medicine outpatient clinic. The average intensity of the symptom over the last 24 hours is assessed with an 11-point NRS that ranges from 0 (no symptom) to 10 (worst intensity). Recently, Hui et al conducted a retrospective analysis of 796 patients with cancer and identified what constitutes a minimal clinically important difference. This was done to record improvement and deterioration for each ESAS symptom, including fatigue. When using the sensitivity-specificity approach, the optimal cutoffs in ESAS physical and total symptom distress scores were !3 for improvement with moderate sensitivities and specificities (ie, !59% and !80%). 14 Additionally, a wide variety of pharmacologic and nonpharmacologic interventions have been proposed to treat CRF. However, there is limited evidence in terms of treatments, such as exercise, 15 corticosteroids, 16 psychostimulants, [17] [18] [19] ginseng, [20] [21] [22] [23] and vitamin D, 24 for CRF. Psychostimulants seem to be superior to placebos for moderate-to-severe fatigue, but most of the studies have been limited by a small sample size. [25] [26] [27] The mechanism behind the evidence for methylphenidate is rebalancing dopamine neurotransmission, which is presumptively altered in fatigue. Methylphenidate blocks reuptake of dopamine, making it more available at synaptic clefts. 28, 29 Although several randomized clinical trials with methylphenidate (5-50 mg/d) have shown mixed results, systemic reviews suggest that methylphenidate may be effective in the management of CRF. However, optimal patients' selection, dosage, and duration of treatment remain unclear. 30, 31 The mechanism behind ginseng benefits seems to be improvement in muscle metabolism through the adenosine monophosphate-activated protein kinase and reduction in inflammatory responses thought to cause fatigue in cancer. [32] [33] [34] Statistically significant improvements were observed with 2000 mg/d of American ginseng (Panax quinquefolius) for CRF. Following treatment, improvement was noted at 8 weeks in an overall study population and at 4 weeks in the active cancer treatment patient group. 35 Both American ginseng and methylphenidate have been used safely in individuals with cancer and have few drug interactions. [36] [37] [38] [39] For possible synergistic purposes, concurrent treatments with both agents have been the practice for some patients with CRF in our Palliative Medicine clinic.
The purpose of this study was to retrospectively review the feasibility, safety, and potential efficacy of treating CRF with methylphenidate and American ginseng combination therapy.
Methods

Design
This was a retrospective medical record review to evaluate the safety and effectiveness of combination therapy with methylphenidate and American ginseng.
Review of Medical Records
We reviewed the electronic medical records of 857 patients seen in our Palliative Medicine outpatient clinic between February 1, 2015, and December 31, 2015, to identify those who were prescribed a combination of methylphenidate and American ginseng.
All patients were 18 years or older; had confirmed pathologic diagnosis of malignancy; were undergoing active treatment with chemotherapy, radiation therapy, or concurrent chemotherapy and radiation; or were on active observational status. Patients included in this review completed an ESAS assessment during their clinic visit. An ESAS fatigue rating on an NRS of 4 or higher was considered clinically significant and was a requirement to be included in the review.
Data Collection
We extracted descriptive data from the medical records including patient's sex, age, cancer type and stage, and cancer treatment status during the study period. We obtained ESAS NRS scores for fatigue over the last 24 hours pre-and postintervention, which was on average 4 weeks.
Statistical Analysis
Baseline characteristics were summarized with mean, variation for continuous data, and frequencies for categorical data. The primary objectives of the study were to evaluate the safety and feasibility and explore the potential efficacy of the combination therapy.
The statistical analysis was conducted with 2 outcomes: (1) safety measured with standard adverse effect monitoring and (2) responder's rate and change in ESAS score. A patient is defined as a responder if their fatigue scores decreased by 3 or more on the NRS for fatigue after receiving the combination therapy. The Clopper-Pearson method was used to compute a 95% confidence interval for outcomes. A paired t test or its nonparametric alternative was used to assess fatigue score changes during the combination treatment. A logistic regression analysis and generalized linear modeling were utilized to explore the association with potential predictors. As this was a retrospective feasibility study, no formal sample size justification was provided. A 2-sided P value of <.05 was considered significant and no multiplicity adjustment is planned.
Human Participants/Ethical Considerations
This study was reviewed and approved by scientific review committee and institutional review board.
Results
We reviewed the electronic medical records of 857 patients seen in our Palliative Medicine outpatient clinic between February 1, 2015, and December 31, 2015. We identified 28 patients who were prescribed both methylphenidate and American ginseng for their moderate-to-severe fatigue (ESAS ! 4 or higher) during the review period. All 28 patients were on systemic chemotherapy, radiation therapy, or both. Ten patients did not comply with the instructions of the prescribed regimen. Four patients were lost to follow-up. One patient died due to cancer progression prior to the first follow-up. Four patients took the methylphenidate, but not American ginseng. One patient took only American ginseng. The remaining 18 patients were compliant with the physician's prescription and instructions. However, there were 3 patients who terminated the combination therapy. Two patients stopped methylphenidate within 3 to 5 days with Common Terminology Criteria for Adverse Events version 4.03 grade 2 of anxiety or diarrhea (2 of 18, 11%). One patient stopped due to personal preference.
Fifteen patients completed prescribed combination therapy per instructions. Among these 15 patients, all had hemoglobin level of 8 g/dL or higher during the antifatigue treatment. There were no patients with poorly controlled chronic lung disease, heart failure, or thyroid disease. There were 3 patients who had thyroid-stimulating hormone screening during the treatment. Two had normal results, although 1 patient was found with hypothyroidism at follow-up. However, the patient's record was still included into this study, because levothyroxine was added after follow-up evaluation.
The average age was 52.4 years (SD 9.89). Eight patients were female. Although all took American ginseng, the identification of the brand name and quantity of ginsenosides in the American ginseng capsule was not possible. Nonetheless, all included patient records documented intake of American ginseng capsules with a dose of 2000 mg/d. Methylphenidate doses varied (10-40 mg/d) depending on tolerability. Twelve (80%) patients were on 10 mg of methylphenidate twice a day, morning and noon ( Table 1 ). The cancers treated consisted of both solid and hematologic malignancy (Table 1 ). There were no additional documented recommendations besides these combination agents by physicians in terms of known CRF management such as steroid, vitamin D, and exercise.
We identified the prescore from the visit date when combination therapy was prescribed and postscore from the visit following methylphenidate and American ginseng combination therapy (date interval between pre-and postintervention: mean, 30.5 days; SD, 7.78). There was significant reduction in the fatigue score (mean score 6.93-4.13) from the pre-to postscore records (score reduction: mean: À2.8; SD: 1.61; median: À3; P < .0002* [*refers to statistically significant]). As a result of the limited sample size, we were unable to perform statistical analysis for safety or efficacy by cancer type, cancer treatment type, or different dosage of methylphenidate (Table 2 , Figures  2 and 3) . In our review, 11% of patients developed a grade 2 adverse effect (2 of 18). Sixty percent of patients who received combination therapy reported significant subjective reductions in fatigue (cutoff value: !3; reduction of fatigue score from baseline: 80% ! 2, 60% ! 3, and 46.7% ! 4). There were no associations between age or gender and fatigue score changes. (Table 3 , Figures 4 and 5) .
Discussion
In our retrospective review, combination therapy with methylphenidate and American ginseng proved to be feasible. Further investigation could proceed, with the expectation of minimal risk of adverse effects.
Due to the fact that fatigue is subjective, the most reliable way to measure severity of fatigue remains unclear, although several assessment tools have been developed. Fatigue responses could change with the instruments used to measure subjective fatigue or the time frame of fatigue reports. The statistical outcome may also depend on the sensitivity of the scale to change over time. 40, 41 This study measured the change of severity of the fatigue score over the last 24 hours using the ESAS score.
Methylphenidate has been investigated in several different clinical trials and has shown mixed results in terms of efficacy. The subgroup analysis suggests that it may be more beneficial in moderate-to-severe CRF with long-term treatment (more than 4 weeks). 42, 43 It remains uncertain whether the limited efficacy of methylphenidate in CRF is dose related. In most clinical trials, methylphenidate has been relatively safe within common therapeutic doses (10-40 mg/d). 44 However, the clinical evidence of benefit with methylphenidate in CRF is still weak, since most studies were of a small sample size, open label, and used different dosage or fatigue scales. The most recent NCCN guideline as well as Cochrane Database Review confirmed that methylphenidate may be helpful with modest efficacy in moderate-to-severe fatigue, although further clinical investigation is needed. 1, 44 Ginseng has been traditionally used in East Asia for patients with cancer to boost energy levels. [45] [46] [47] [48] [49] However, there are few clinical trials with American ginseng for CRF in humans. One double-blind study suggested the safety and benefit of American ginseng when taking 2000 mg daily for CRF over an 8-week period. 35, 50 In recent study, even high dose of extracted (drug extract ratio 1:3-5) Panax ginseng 800 mg/d was safe and ameliorated CRF.21 However, ginseng is not generally identified as a standard first-line treatment in CRF. There is no long-term clinical data available (more than 8 weeks) for each type of single therapy; hence, long-term safety needs to be established.
Although little is known about the pathophysiology of CRF, the known pharmacologic mechanisms of methylphenidate and American ginseng action are different. Therefore, a reasonable future endeavor is to begin investigation on the hypothesis that combination therapy with methylphenidate and American ginseng is superior to single therapy with either substance individually.
This study has several limitations. The study was an open-label, nonrandomized retrospective review, consisting of a small sample size with no control group and no 51 ; therefore, some changes in the reported severity of fatigue could have been the result of a placebo effect.
Conclusion
Our data supported that the combination treatment of methylphenidate and American ginseng had no discernible associated toxicities and showed potential clinical benefit in CRF. It would be reasonable to consider further investigation to measure safety and efficacy with a larger sample size, randomized double-blind study, or different dose combination. 
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